Stocks · News reference
HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $7 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio,
Chardan Capital analyst Gautam Chukka initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.